European Commission approves Roche ’s MabThera (rituximab) for a rare autoimmune disease

Roche today announced that the European Commission has approved MabThera ® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition characterised by progressive painful blistering of the skin and/or mucous membranes.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news